Updated results from the BEACON trial show unprecedented overall survival in the second-line treatment of CRC
Triplet targeted combination therapy appears to induce potent BRAF kinase signalling inhibition in patients with BRAFV600E-mutated metastatic colorectal cancer
Off-label therapies: what is their future?
Many studies presented at the Congress hint at promising treatments for rare sarcomas but access to effective treatments remains a challenge
ClarIDHy trial reports a small improvement in progression-free survival
Targeting isocitrate dehydrogenase 1 mutations in cholangiocarcinoma is a promising strategy
Chemotherapy plus endocrine therapy increases long-term recurrence-free survival in women with high-risk HR+ breast cancer
Results from TAILORx trial presented at ESMO 2019
